GlobalData on MSN5d
Positive Phase III results for linerixibat in cholestatic pruritus treatment for PBC patients
PBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.
The Pharma Letter6d
Linerixibat shows positive Phase III results in PBC, says GSK
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...
Monthly Prescribing Reference5d
Linerixibat Reduces Pruritus in Primary Biliary Cholangitis Trial
Topline results were announced from a phase 3 trial evaluating linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Pharmabiz6d
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...
pharmaphorum6d
GSK drug raises hopes for patients with PBC itch
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
Investing6d
GSK's phase III trial of linerixibat shows promise for PBC itch
GSK plc (LSE/NYSE: LON:GSK) has announced positive results from its phase III GLISTEN trial of linerixibat, an investigational drug aimed at treating cholestatic pruritus (persistent itching) in ...